HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 price target.
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 price target.